Article Information
History
- December 12, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Brit Ellen Rød, MD1,2,3,*,
- Einar A. Høgestøl, MD, PhD4,5,6,
- Øivind Torkildsen, MD, PhD1,2,
- Kjetil Bjørnevik, MD, PhD7,
- Jon Michael Gran, PhD8,
- Mathias H. Øverås, MD4,5,
- Marton König, MD, PhD4,5,
- Elisabeth G. Celius, MD, PhD4,5,
- Kjell-Morten Myhr, MD, PhD1,2,
- Stig Wergeland, MD, PhD1,2,3 and
- Gro O. Nygaard, MD, PhD4,5
- 1Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway
- 2Department of Clinical Medicine, University of Bergen, Bergen, Norway
- 3The Norwegian Multiple Sclerosis Registry and Biobank, Haukeland University Hospital, Bergen, Norway
- 4Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- 5Department of Neurology, Oslo University Hospital, Oslo, Norway
- 6Department of Psychology, Oslo University Hospital, Oslo, Norway
- 7Departments of Epidemiology and Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA, USA
- 8Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
- ↵*Corresponding author
Brit Ellen Rød Neuro-SysMed, Department of Neurology Haukeland University Hospital Bergen, Norway. E-mail address: brit.ellen.rod{at}helse-bergen.no
Posted December 12, 2024.
Comparative Effectiveness of Rituximab and Cladribine in Relapsing-Remitting Multiple Sclerosis: A Target Trial Emulation
